Novo says Wegovy cut risk of heart attack, death by 57% compared to tirzepatide

Novo Nordisk (NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology, ESC, Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events, MACE, with Wegovy compared with Eli Lilly’s (LLY) tirzepatide treatment in people with overweight or obesity and established CVD without diabetes. Compared with tirzepatide, Wegovy showed a significant 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, who did not have any gaps in their treatment lasting more than 30 days. There were 15 of these cardiovascular events recorded with Wegovy, and 39 events were recorded with tirzepatide. The average follow-up duration was 3.8 months for the Wegovy group and 4.3 months for the tirzepatide group. In all treated people, regardless of any gaps in their treatment, Wegovy showed a significant 29% risk reduction for heart attack, stroke and death from any cause compared with tirzepatide.